12:00 AM
 | 
Nov 11, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

SP-333: Phase II started

Synergy began a double-blind, placebo-controlled Phase II trial to evaluate 1, 3 and 6 mg oral SP-333 once daily for 4 weeks in about 260 OIC...

Read the full 108 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >